Compare Stocks: CUS, IVA, MGX, and NVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUS Chemtrade Electrochem Inc,		C$0.00	C$1.18 ▼ C$1.65	C$306.50M	N/A	271,090 shs	13,269 shs
IVA Inventiva	$3.53 +4.7%	$4.41	$3.11 ▼ $7.98	$699.97M	0.71	1.58 million shs	3.42 million shs
MGX Metagenomi	$1.14 -0.9%	$1.19	$1.07 ▼ $3.95	$43.44M	0.67	152,832 shs	132,000 shs
NVS Novartis	$146.95 +1.0%	$151.62	$121.57 ▼ $170.46	$277.56B	0.45	2.55 million shs	1.95 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUS Chemtrade Electrochem Inc,	0.00%	0.00%	0.00%	0.00%	0.00%
IVA Inventiva	0.00%	-10.85%	-28.30%	-5.07%	-44.30%
MGX Metagenomi	0.00%	+4.55%	-3.36%	-4.17%	-49.78%
NVS Novartis	0.00%	+3.57%	-5.37%	-7.66%	+17.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUS Chemtrade Electrochem Inc,		C$0.00	C$1.18 ▼ C$1.65	C$306.50M	N/A	271,090 shs	13,269 shs
IVA Inventiva	$3.53 +4.7%	$4.41	$3.11 ▼ $7.98	$699.97M	0.71	1.58 million shs	3.42 million shs
MGX Metagenomi	$1.14 -0.9%	$1.19	$1.07 ▼ $3.95	$43.44M	0.67	152,832 shs	132,000 shs
NVS Novartis	$146.95 +1.0%	$151.62	$121.57 ▼ $170.46	$277.56B	0.45	2.55 million shs	1.95 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUS Chemtrade Electrochem Inc,	0.00%	0.00%	0.00%	0.00%	0.00%
IVA Inventiva	0.00%	-10.85%	-28.30%	-5.07%	-44.30%
MGX Metagenomi	0.00%	+4.55%	-3.36%	-4.17%	-49.78%
NVS Novartis	0.00%	+3.57%	-5.37%	-7.66%	+17.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUS Chemtrade Electrochem Inc,	0.00	N/A	N/A	N/A
IVA Inventiva	3.09	Buy	$15.75	346.18% Upside
MGX Metagenomi	2.75	Moderate Buy	$6.00	426.32% Upside
NVS Novartis	2.38	Hold	$153.00	4.12% Upside

Current Analyst Ratings Breakdown

Latest CUS, IVA, MGX, and NVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $14.00
9/10/2026	NVS Novartis	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$123.00 ➝ $136.00
9/10/2026	NVS Novartis	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$123.00 ➝ $136.00
9/9/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	NVS Novartis	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
9/8/2026	NVS Novartis	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform
8/26/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$7.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUS Chemtrade Electrochem Inc,	N/A	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	$5.07M	144.62	N/A	N/A	($0.22) per share	-16.05
MGX Metagenomi	$25.21M	1.71	N/A	N/A	$4.22 per share	0.27
NVS Novartis	$54.53B	5.14	$10.84 per share	13.55	$22.04 per share	6.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUS Chemtrade Electrochem Inc,	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	-$87.87M	-$2.49	N/A	N/A	N/A	-384.61%	-63.65%	-44.52%	11/10/2026 (Estimated)
NVS Novartis	$13.98B	$6.63	22.16	14.96	2.81	23.29%	38.56%	14.47%	10/27/2026 (Estimated)

Latest CUS, IVA, MGX, and NVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026 TU	IVA Inventiva	N/A	-$0.1450	N/A	-$0.1450	N/A	$0.75 million
8/10/2026	Q2 2026	MGX Metagenomi	-$0.5531	-$0.73	-$0.1769	-$0.73	$3.01 million	($0.26) million
7/21/2026	Q2 2026	NVS Novartis	$2.17	$2.41	+$0.24	$1.71	$14.07 billion	$14.41 billion
6/30/2026	Q2 2026	NVS Novartis	N/A	$2.41	N/A	$1.71	N/A	$14.95 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUS Chemtrade Electrochem Inc,	C$0.02	2.44%	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
NVS Novartis	$3.08	2.10%	+5.28%	46.46%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUS Chemtrade Electrochem Inc,	N/A	N/A	N/A
IVA Inventiva	N/A	3.16	3.16
MGX Metagenomi	N/A	4.50	4.50
NVS Novartis	0.89	0.86	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUS Chemtrade Electrochem Inc,	N/A
IVA Inventiva	19.06%
MGX Metagenomi	N/A
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
CUS Chemtrade Electrochem Inc,	N/A
IVA Inventiva	32.00%
MGX Metagenomi	12.50%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUS Chemtrade Electrochem Inc,	60	186.89 million	N/A	Not Optionable
IVA Inventiva	73	207.71 million	141.24 million	Not Optionable
MGX Metagenomi	113	37.78 million	33.06 million	N/A
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable

CUS, IVA, MGX, and NVS Headlines

Recent News About These Companies

Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?

1 hour ago | finance.yahoo.com

Zacks Research Brokers Boost Earnings Estimates for Novartis

September 28 at 1:28 AM | americanbankingnews.com

Novartis Stock Earnings Estimates Raised by Zacks Research

September 28 at 1:26 AM | marketbeat.com

Novartis AG $NVS Shares Sold by State Street Corp

September 26 at 3:36 AM | marketbeat.com

A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team

September 26 at 3:15 AM | finance.yahoo.com

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

September 25 at 10:11 PM | insidermonkey.com

FY2027 EPS Estimates for Novartis Lifted by Erste Group Bank

September 25 at 1:13 AM | americanbankingnews.com

Envestnet Asset Management Inc. Acquires 19,595 Shares of Novartis AG $NVS

September 24, 2026 | marketbeat.com

QRG Capital Management Inc. Raises Stock Position in Novartis AG $NVS

September 23, 2026 | marketbeat.com

Novartis stock gains 0.62 percent at the close

September 23, 2026 | ad-hoc-news.deA

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

September 23, 2026 | zacks.com

FY2027 EPS Estimates for Novartis Raised by Erste Group Bank

September 23, 2026 | marketbeat.com

Novartis stock ends the day at USD 141.43 after the close

September 23, 2026 | ad-hoc-news.deA

BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 Mln

September 22, 2026 | rttnews.com

Erste Group Bank Forecasts Increased Earnings for Novartis

September 22, 2026 | marketbeat.com

Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial

September 21, 2026 | insidermonkey.com

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

September 21, 2026 | zacks.com

Novartis' Pipeline In Focus After A Series Of Clinical Setbacks

September 21, 2026 | rttnews.com

EMA panel backs Novartis Cosentyx for rheumatic condition in EU

September 18, 2026 | streetinsider.com

Novartis Gains Positive CHMP Opinion For Cosentyx In Polymyalgia Rheumatica; EC Decision By Nov '26

September 18, 2026 | rttnews.com

Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years

September 17, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CUS, IVA, MGX, and NVS Company Descriptions

Chemtrade Electrochem Inc, TSE:CUS

Chemtrade Electrochem Inc, formerly Canexus Corp is a Canada-based company engaged in operating North American sodium chlorate production facilities; a North American chlor-alkali production facility and a sodium chlorate and chlor-alkali production facility. Its segments are North America Sodium Chlorate, North America Chlor-alkali (NACA) and South America (sodium chlorate and chlor-alkali). The North America Sodium Chlorate segment sells sodium chlorate to the South America segment and provides transloading services to the NACA segment for caustic soda transloaded from barges into trucks for delivery to NACA customers. It produces sodium chlorate in Beauharnois, Quebec; Brandon, Manitoba, and Nanaimo, British Columbia; chlor-alkali products (caustic soda, chlorine, and hydrochloric acid) in North Vancouver, British Columbia, and sodium chlorate and chlor-alkali products in Espirito Santo, Brazil. It caters its production to the pulp and paper, water treatment and oil and gas sectors.

Inventiva NASDAQ:IVA

$3.53 +0.16 (+4.75%)

Closing price 04:00 PM Eastern

Extended Trading

$3.58 +0.05 (+1.33%)

As of 07:58 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Metagenomi NASDAQ:MGX

$1.14 -0.01 (-0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$1.12 -0.01 (-1.32%)

As of 07:50 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Novartis NYSE:NVS

$146.95 +1.49 (+1.02%)

Closing price 03:59 PM Eastern

Extended Trading

$147.37 +0.42 (+0.29%)

As of 07:56 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUS, IVA, MGX, and NVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUS, IVA, MGX, and NVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUS, IVA, MGX, and NVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CUS, IVA, MGX, and NVS Company Descriptions

Chemtrade Electrochem Inc, TSE:CUS

Inventiva NASDAQ:IVA

Metagenomi NASDAQ:MGX

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUS, IVA, MGX, and NVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUS, IVA, MGX, and NVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUS, IVA, MGX, and NVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CUS, IVA, MGX, and NVS Company Descriptions

Chemtrade Electrochem Inc, TSE:CUS

Inventiva NASDAQ:IVA

Metagenomi NASDAQ:MGX

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools